Ajanta Pharma Share Price Gains Over 3% on Licensing Deal with Biocon for Semaglutide

Written by: Team Angel OneUpdated on: 24 Dec 2025, 5:57 pm IST

Ajanta Pharma partners with Biocon to market Semaglutide in 26 countries, enhancing diabetes care access in Africa, the Middle East, and Central Asia.

Ajanta Pharma Limited has announced a strategic partnership with Biocon Limited to market Semaglutide, a GLP-1 receptor agonist, in 26 countries.

This collaboration aims to improve diabetes care in Africa, the Middle East, and Central Asia.

Details of the Ajanta-Biocon Agreement

On December 23, 2025, Ajanta Pharma Ltd. revealed its in-licensing agreement with Biocon Ltd. for Semaglutide.

Under this agreement, Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East, and Central Asia.

Semaglutide is designed to improve glycaemic control in adults. The product patent is set to expire in most of these markets by March 2026. Ajanta plans to commercialise the product following regulatory approvals, expected in late 2026 or early 2027.

Ajanta Pharma's Market Presence

Ajanta Pharma has established a strong branded generic business with a presence in over 30 countries across Africa, South-East Asia, Central Asia, and the Middle East.

The company operates in various therapeutic segments, including cardiology, antidiabetic, ophthalmology, antibiotic, antimalarial, pain, gynaecology, paediatric, and general health products.

Ajanta has more than 220 brands in emerging markets, with many holding leadership positions in their respective segments.

Biocon's Strategic Expansion

Biocon Limited, a global biopharmaceutical company, focuses on enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer, and autoimmune diseases.

The partnership with Ajanta Pharma is a strategic step to expand Biocon’s GLP-1 portfolio and maximise the value of its scientific investments in complex peptide development.

This collaboration will enable broader and more affordable access to Semaglutide for patients in the targeted regions.

Ajanta Pharma Share Price Performance

As of December 24, 2025, at 11:52 AM, Ajanta Pharma share price on NSE was trading at ₹2,771.60 up by 3.88% from the previous closing price.

Conclusion

The collaboration between Ajanta Pharma and Biocon marks a significant development in diabetes care across Africa, the Middle East, and Central Asia. By leveraging Ajanta's extensive market presence and Biocon's innovative capabilities, the partnership aims to provide broader access to Semaglutide, enhancing health outcomes in these regions.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Dec 24, 2025, 12:27 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More